Cargando…
Response Rate of the Third and Fourth Doses of the BNT162b2 Vaccine Administered to Cancer Patients Undergoing Active Anti-Neoplastic Treatments
The BNT162b2 vaccine is globally used for preventing morbidity and mortality related to COVID-19. Cancer patients have had priority for receiving the vaccine due to their diminished immunity. This study reports the response rate of administering the third and fourth vaccine doses to cancer patients...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10594524/ https://www.ncbi.nlm.nih.gov/pubmed/37873772 http://dx.doi.org/10.3390/diseases11040128 |
_version_ | 1785124670334304256 |
---|---|
author | Agbarya, Abed Sarel, Ina Ziv-Baran, Tomer Schwartz, Orna Shechtman, Yelena Kozlener, Ella Khoury, Rasha Sheikh-Ahmad, Mohammad Saiegh, Leonard Swaid, Forat Ahmad, Asala Abu Janzic, Urska Brenner, Ronen |
author_facet | Agbarya, Abed Sarel, Ina Ziv-Baran, Tomer Schwartz, Orna Shechtman, Yelena Kozlener, Ella Khoury, Rasha Sheikh-Ahmad, Mohammad Saiegh, Leonard Swaid, Forat Ahmad, Asala Abu Janzic, Urska Brenner, Ronen |
author_sort | Agbarya, Abed |
collection | PubMed |
description | The BNT162b2 vaccine is globally used for preventing morbidity and mortality related to COVID-19. Cancer patients have had priority for receiving the vaccine due to their diminished immunity. This study reports the response rate of administering the third and fourth vaccine doses to cancer patients receiving active anti-neoplastic treatment. A total of 142 patients received two doses of the mRNA-based BNT162b2 COVID-19 vaccine, while 76 and 25 patients received three and four doses, respectively. The efficacy of the humoral response following two vaccine doses was diminished in cancer patients, especially in the group of patients receiving chemotherapy. In a multivariate analysis, patients who received three and four BNT162b2 vaccine doses were more likely to have antibody titers in the upper tertile compared to patients who received two doses of the vaccine (odds ratio (OR) 7.62 (95% CI 1.38–42.12), p = 0.02 and 17.15 (95% CI 5.01–58.7), p < 0.01, respectively). Unlike the response after two doses, the third and fourth BNT162b2 vaccine booster doses had an increased efficacy of 95–100% in cancer patients while undergoing active treatment. This result could be explained by different mechanisms including the development of memory B cells. |
format | Online Article Text |
id | pubmed-10594524 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-105945242023-10-25 Response Rate of the Third and Fourth Doses of the BNT162b2 Vaccine Administered to Cancer Patients Undergoing Active Anti-Neoplastic Treatments Agbarya, Abed Sarel, Ina Ziv-Baran, Tomer Schwartz, Orna Shechtman, Yelena Kozlener, Ella Khoury, Rasha Sheikh-Ahmad, Mohammad Saiegh, Leonard Swaid, Forat Ahmad, Asala Abu Janzic, Urska Brenner, Ronen Diseases Article The BNT162b2 vaccine is globally used for preventing morbidity and mortality related to COVID-19. Cancer patients have had priority for receiving the vaccine due to their diminished immunity. This study reports the response rate of administering the third and fourth vaccine doses to cancer patients receiving active anti-neoplastic treatment. A total of 142 patients received two doses of the mRNA-based BNT162b2 COVID-19 vaccine, while 76 and 25 patients received three and four doses, respectively. The efficacy of the humoral response following two vaccine doses was diminished in cancer patients, especially in the group of patients receiving chemotherapy. In a multivariate analysis, patients who received three and four BNT162b2 vaccine doses were more likely to have antibody titers in the upper tertile compared to patients who received two doses of the vaccine (odds ratio (OR) 7.62 (95% CI 1.38–42.12), p = 0.02 and 17.15 (95% CI 5.01–58.7), p < 0.01, respectively). Unlike the response after two doses, the third and fourth BNT162b2 vaccine booster doses had an increased efficacy of 95–100% in cancer patients while undergoing active treatment. This result could be explained by different mechanisms including the development of memory B cells. MDPI 2023-09-26 /pmc/articles/PMC10594524/ /pubmed/37873772 http://dx.doi.org/10.3390/diseases11040128 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Agbarya, Abed Sarel, Ina Ziv-Baran, Tomer Schwartz, Orna Shechtman, Yelena Kozlener, Ella Khoury, Rasha Sheikh-Ahmad, Mohammad Saiegh, Leonard Swaid, Forat Ahmad, Asala Abu Janzic, Urska Brenner, Ronen Response Rate of the Third and Fourth Doses of the BNT162b2 Vaccine Administered to Cancer Patients Undergoing Active Anti-Neoplastic Treatments |
title | Response Rate of the Third and Fourth Doses of the BNT162b2 Vaccine Administered to Cancer Patients Undergoing Active Anti-Neoplastic Treatments |
title_full | Response Rate of the Third and Fourth Doses of the BNT162b2 Vaccine Administered to Cancer Patients Undergoing Active Anti-Neoplastic Treatments |
title_fullStr | Response Rate of the Third and Fourth Doses of the BNT162b2 Vaccine Administered to Cancer Patients Undergoing Active Anti-Neoplastic Treatments |
title_full_unstemmed | Response Rate of the Third and Fourth Doses of the BNT162b2 Vaccine Administered to Cancer Patients Undergoing Active Anti-Neoplastic Treatments |
title_short | Response Rate of the Third and Fourth Doses of the BNT162b2 Vaccine Administered to Cancer Patients Undergoing Active Anti-Neoplastic Treatments |
title_sort | response rate of the third and fourth doses of the bnt162b2 vaccine administered to cancer patients undergoing active anti-neoplastic treatments |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10594524/ https://www.ncbi.nlm.nih.gov/pubmed/37873772 http://dx.doi.org/10.3390/diseases11040128 |
work_keys_str_mv | AT agbaryaabed responserateofthethirdandfourthdosesofthebnt162b2vaccineadministeredtocancerpatientsundergoingactiveantineoplastictreatments AT sarelina responserateofthethirdandfourthdosesofthebnt162b2vaccineadministeredtocancerpatientsundergoingactiveantineoplastictreatments AT zivbarantomer responserateofthethirdandfourthdosesofthebnt162b2vaccineadministeredtocancerpatientsundergoingactiveantineoplastictreatments AT schwartzorna responserateofthethirdandfourthdosesofthebnt162b2vaccineadministeredtocancerpatientsundergoingactiveantineoplastictreatments AT shechtmanyelena responserateofthethirdandfourthdosesofthebnt162b2vaccineadministeredtocancerpatientsundergoingactiveantineoplastictreatments AT kozlenerella responserateofthethirdandfourthdosesofthebnt162b2vaccineadministeredtocancerpatientsundergoingactiveantineoplastictreatments AT khouryrasha responserateofthethirdandfourthdosesofthebnt162b2vaccineadministeredtocancerpatientsundergoingactiveantineoplastictreatments AT sheikhahmadmohammad responserateofthethirdandfourthdosesofthebnt162b2vaccineadministeredtocancerpatientsundergoingactiveantineoplastictreatments AT saieghleonard responserateofthethirdandfourthdosesofthebnt162b2vaccineadministeredtocancerpatientsundergoingactiveantineoplastictreatments AT swaidforat responserateofthethirdandfourthdosesofthebnt162b2vaccineadministeredtocancerpatientsundergoingactiveantineoplastictreatments AT ahmadasalaabu responserateofthethirdandfourthdosesofthebnt162b2vaccineadministeredtocancerpatientsundergoingactiveantineoplastictreatments AT janzicurska responserateofthethirdandfourthdosesofthebnt162b2vaccineadministeredtocancerpatientsundergoingactiveantineoplastictreatments AT brennerronen responserateofthethirdandfourthdosesofthebnt162b2vaccineadministeredtocancerpatientsundergoingactiveantineoplastictreatments |